QED Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Palo Alto CA United States (2018)

Organization Overview

First Clinical Trial
2019
NCT03773302
First Marketed Drug
2021
infigratinib
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

QED THERAP | QED Therapeutics | QED Therapeutics, Inc.